Azatadine

Not to be confused with azetidine.
Azatadine
Clinical data
Trade namesOptimine
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Identifiers
  • 11-(1-Methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H22N2
Molar mass290.410 g·mol−1
3D model (JSmol)
  • n4c3\C(=C1/CCN(C)CC1)c2ccccc2CCc3ccc4
  • InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3 checkY
  • Key:SEBMTIQKRHYNIT-UHFFFAOYSA-N checkY
  (verify)

Azatadine (Optimine) is a first-generation antihistamine and anticholinergic drug that was synthesized in 1963 by Schering-Plough, a former American pharmaceutical company.[1][2]

It was patented in 1967.[3] It has been succeeded by both loratadine and desloratadine.[4]: 53  and marketing approvals have been widely withdrawn.[5][6][7][8]: 290 [9]

  1. ^ Katelaris C (December 1990). "Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis". Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–7. PMID 1982614.
  2. ^ Small P, Barrett D, Biskin N (February 1990). "Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation". Annals of Allergy. 64 (2 Pt 1): 129–31. PMID 1968324.
  3. ^ US 3326924, Villani FJ, Caldwell W, "Azatadine", issued 1967 
  4. ^ Horak F (2010). "Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4". In Pawankar R, Holgate ST, Rosenwasser LJ (eds.). Allergy Frontiers:Therapy and Prevention. Vol. 5. Springer Science & Business Media. ISBN 9784431993629.
  5. ^ "Azatadine". Drugs.com.
  6. ^ Food and Drug Administration (2005). "Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications". Federal Register 70 FR 10651.
  7. ^ Food and Drug Administration (2007). "Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions". Federal Register 72 FR 8184.
  8. ^ "Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals" (PDF). Department of Economic and Social Affairs of the United Nations Secretariat. New York: United Nations. 2005.
  9. ^ "OGD Suitability Tracking Report (Sorted by Drug Name)". FDA.